3 Pharma Cdmo and Distribution Stocks With a Strong Future Roadmap: Innova Captab, Entero Healthcare Solutions and Alembic Pharmaceuticals
- October 8, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Innova Captab Rs 1,166.20, P/E 43.32. Entero Healthcare Rs 1,713.30, P/E 44.49. Alembic Rs 833.80, P/E 23.75. Closing prices of 7 Oct 2026.
Quick Answer
Pharma CDMO and distribution stocks with the clearest long-term roadmaps today include Innova Captab in contract manufacturing of pharma formulations and branded generics, Entero Healthcare Solutions in healthcare product distribution and pharmacies and Alembic Pharmaceuticals in branded generics and active ingredients. FY26 revenue growth was 30.4% at Innova Captab, 28.7% at Entero Healthcare and 10.2% at Alembic. P/E stands at 43.32 for Innova Captab (industry 37.76), 44.49 for Entero Healthcare (industry 37.76) and 23.75 for Alembic (industry 37.76). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Pharma CDMO and distribution stocks give investors exposure to contract drug makers, healthcare distributors and a branded generics maker. Results depend on customer orders, product launches and working capital, which is why margins and cash flow matter as much as headline growth.
This list covers three branded generic and distribution stocks: Innova Captab for contract manufacturing of pharma formulations and branded generics, Entero Healthcare Solutions for healthcare product distribution and pharmacies and Alembic Pharmaceuticals for branded generics and active ingredients. Every figure comes from the latest reported financials and the 7 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma Cdmo and Distribution Stocks?
Pharma CDMO and distribution stocks are shares of companies that make medicines for other firms, distribute healthcare products or sell branded generics. Results depend on contract wins, launches, working capital and operating margin, so a deepening customer base and tight inventory control separate the stronger names.
Pharma Cdmo and Distribution Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three pharma CDMO and distribution stocks as of the 7 October 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Innova Captab | 1,166.20 | 6,674 | 43.32 | 37.76 | 12.92% | 0.32 |
| Entero Healthcare Solutions | 1,713.30 | 7,458 | 44.49 | 37.76 | 6.81% | 0.40 |
| Alembic Pharmaceuticals | 833.80 | 16,375 | 23.75 | 37.76 | 11.89% | 0.25 |
Among branded generic and distribution stocks, Alembic trades below the industry P/E, while Innova Captab and Entero Healthcare trade at a premium to the industry multiple.
Why Do Pharma Cdmo and Distribution Stocks Have a Strong Roadmap in India?
Pharma CDMO and distribution stocks have a strong roadmap in India because drug makers outsource more production, hospitals and pharmacies are formalising and branded generics keep gaining share. Three drivers stand out.
- Outsourced manufacturing: Pharma firms hand more production to specialists.
- Formal healthcare distribution: Hospitals and pharmacies prefer organised suppliers.
- Branded generic growth: Doctor-led brands keep gaining share.
Innova Captab: Contract Manufacturing of Formulations Anchors the Roadmap
Innova Captab’s roadmap rests on contract manufacturing of pharma formulations and branded generics, with new customers and plant additions supporting revenue.
Revenue grew from Rs 803.41 crore in FY22 to Rs 1,637.44 crore in FY26, a 103.8% rise, and FY26 revenue was 30.4% higher than FY25. FY26 net profit rose 9.9% to Rs 140.92 crore. Over four years, net profit rose from Rs 63.95 crore in FY22 to Rs 140.92 crore. In Q1 FY27, revenue grew 32.8% to Rs 472.86 crore, and net profit rose 42.3% to Rs 44.13 crore. Operating margin was 15.36% in FY26 and 15.96% in Q1 FY27 against 16.09% a year earlier.
Debt to equity is 0.32 and return on equity is 12.92%. FY26 operating cash flow was Rs 116.52 crore against capital expenditure of Rs 68.35 crore. Innova Captab paid a dividend of Rs 2 per share for FY26, a yield of 0.17%. At a P/E of 43.32 against an industry P/E of 37.76, the stock trades above its industry multiple.
What to watch: Return on equity of 12.92% is modest. The P/E of 43.32 sits above the industry P/E of 37.76, so earnings delivery matters for the valuation.
Entero Healthcare Solutions: Healthcare Distribution and Pharmacies Drive the Pipeline
Entero Healthcare’s roadmap rests on healthcare product distribution and pharmacies, with hospital and pharmacy customers and new categories supporting volumes.
Revenue grew from Rs 2,526.55 crore in FY22 to Rs 6,610.45 crore in FY26, a 161.6% rise, and FY26 revenue was 28.7% higher than FY25. FY26 net profit rose 35.8% to Rs 145.84 crore. In Q1 FY27, revenue grew 37.9% to Rs 1,943.51 crore, and net profit rose 72.2% to Rs 52.05 crore. Operating margin was 4.20% in FY26 and 5.15% in Q1 FY27 against 3.98% a year earlier.
Debt to equity is 0.40 and return on equity is 6.81%. FY26 operating cash flow was Rs 96.20 crore against capital expenditure of Rs 67.54 crore. At a P/E of 44.49 against an industry P/E of 37.76, the stock trades above its industry multiple.
What to watch: Return on equity of 6.81% is modest, and net profit margin is only 2.2%, so small cost changes move earnings. The P/E of 44.49 sits above the industry P/E of 37.76, so earnings delivery matters for the valuation.
Alembic Pharmaceuticals: Branded Generics and Active Ingredients Build the Next Leg
Alembic’s roadmap rests on branded generics and active ingredients, with new launches and a wide doctor reach supporting growth.
Revenue grew from Rs 5,356.25 crore in FY22 to Rs 7,399.31 crore in FY26, a 38.1% rise, and FY26 revenue was 10.2% higher than FY25. FY26 net profit rose 15.3% to Rs 670.83 crore. Over four years, net profit rose from Rs 520.94 crore in FY22 to Rs 670.83 crore. In Q1 FY27, revenue grew 26.1% to Rs 2,164.70 crore, and net profit rose 12.2% to Rs 172.36 crore. Operating margin was 15.06% in FY26 and 16.15% in Q1 FY27 against 16.80% a year earlier.
Debt to equity is 0.25 and return on equity is 11.89%. FY26 operating cash flow was Rs 782.73 crore against capital expenditure of Rs 494.88 crore. Alembic paid a dividend of Rs 12 per share for FY26, a yield of 1.44%. At a P/E of 23.75 against an industry P/E of 37.76, the stock trades below its industry multiple.
What to watch: FY25 net profit of Rs 582.01 Cr was lower than the Rs 615.82 Cr of FY24, and return on equity of 11.89% is modest.
Best Pharma Cdmo and Distribution Stocks in India: Innova Captab vs Entero Healthcare vs Alembic on Key Financials
Among the best pharma CDMO and distribution stocks in India, Innova Captab leads on FY26 operating margin and return on equity; Entero Healthcare leads on Q1 FY27 revenue growth and five-year revenue growth; Alembic leads on the lowest P/E. The table puts the numbers side by side.
| Metric | Innova Captab | Entero Healthcare | Alembic |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 1,637.44 | 6,610.45 | 7,399.31 |
| FY26 revenue growth | 30.4% | 28.7% | 10.2% |
| Revenue growth FY22 to FY26 | 103.8% | 161.6% | 38.1% |
| FY26 net profit (Rs Cr) | 140.92 | 145.84 | 670.83 |
| FY26 net profit growth | 9.9% | 35.8% | 15.3% |
| FY26 operating profit margin | 15.36% | 4.20% | 15.06% |
| Q1 FY27 revenue growth (YoY) | 32.8% | 37.9% | 26.1% |
| Q1 FY27 net profit growth (YoY) | 42.3% | 72.2% | 12.2% |
| Return on equity | 12.92% | 6.81% | 11.89% |
| P/E ratio | 43.32 | 44.49 | 23.75 |
| Debt to equity | 0.32 | 0.40 | 0.25 |
| Dividend yield | 0.17% | 0.00% | 1.44% |
| FY26 operating cash flow (Rs Cr) | 116.52 | 96.20 | 782.73 |
Pharma earnings follow contract wins and launches, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Contract Pharma and Healthcare Distribution Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen pharma CDMO and distribution stocks and shortlist contract pharma and healthcare distribution stocks to buy.
- Compare each stock’s P/E with its industry P/E, which is 37.76 for all three here.
- Track operating margin across several quarters, because input costs can move faster than prices.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Check the Univest Screener for live data on these pharma CDMO and distribution stocks
Risks to Consider Before Investing in Pharma Cdmo and Distribution Stocks
- Valuation: Innova Captab and Entero Healthcare trade at 43.32 and 44.49 times earnings against an industry multiple of 37.76.
- Thin margins: Entero Healthcare’s operating margin is only about 4% to 5%.
- Low returns: Entero Healthcare’s ROE is 6.81%.
- Pricing and regulation: Price controls and plant inspections can hit margins.
Download the Univest iOS App or Univest Android App to track Innova Captab, Entero Healthcare and Alembic live.
Final Take: Which Stock Has the Strongest Roadmap?
These three contract pharma and healthcare distribution stocks cover contract pharma manufacturing, healthcare distribution, and branded generics. Innova Captab leads on FY26 operating margin and return on equity; Entero Healthcare leads on Q1 FY27 revenue growth and five-year revenue growth; Alembic leads on the lowest P/E.
Across branded generic and distribution stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the contract pharma and healthcare distribution stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Pharma Cdmo and Distribution Stocks
Which are the best pharma CDMO and distribution stocks in India with a strong roadmap?
Ans. Innova Captab, Entero Healthcare Solutions and Alembic Pharmaceuticals stand out for their roadmaps in contract manufacturing, healthcare distribution and branded generics. FY26 revenue growth was 30.4% at Innova Captab, 28.7% at Entero Healthcare and 10.2% at Alembic, and return on equity ranges from 6.81% to 12.92%.
Is Innova Captab a good stock to buy now?
Ans. Innova Captab has a debt to equity ratio of 0.32, a return on equity of 12.92% and a P/E of 43.32 against an industry P/E of 37.76. Valuation, thin margins and low returns move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Innova Captab, Entero Healthcare and Alembic?
Ans. The P/E ratio is 43.32 for Innova Captab (industry 37.76), 44.49 for Entero Healthcare (industry 37.76) and 23.75 for Alembic (industry 37.76). Only Innova Captab and Entero Healthcare trade at or above the industry multiple.
Which of these pharma CDMO and distribution stocks has the highest return on equity?
Ans. Innova Captab has the highest return on equity at 12.92%, followed by Alembic Pharmaceuticals at 11.89% and Entero Healthcare Solutions at 6.81%.
What are the risks of investing in pharma CDMO and distribution stocks?
Ans. The main risks are premium valuations at two firms, thin distribution margins, a low return on equity and pricing and regulation. Entero Healthcare’s operating margin is only about 4% to 5%.
How did Innova Captab, Entero Healthcare and Alembic perform in Q1 FY27?
Ans. Innova Captab reported revenue of Rs 472.86 crore, up 32.8% year on year, and net profit rose 42.3% to Rs 44.13 crore. Entero Healthcare Solutions reported revenue of Rs 1,943.51 crore, up 37.9% year on year, and net profit rose 72.2% to Rs 52.05 crore. Alembic Pharmaceuticals reported revenue of Rs 2,164.70 crore, up 26.1% year on year, and net profit rose 12.2% to Rs 172.36 crore.
Do pharma CDMO and distribution stocks pay dividends?
Ans. Dividend payouts differ across the three companies. The dividend yield is 0.17% for Innova Captab, 0.00% for Entero Healthcare and 1.44% for Alembic, based on dividends declared for FY26.
How can I invest in pharma CDMO and distribution stocks in India?
Ans. You can buy pharma CDMO and distribution stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.